Wedbush Upgrades Intellia Therapeutics (NTLA) to Outperform

May 3, 2019 6:50 AM EDT
Get Alerts NTLA Hot Sheet
Price: $140.40 +2.47%

Rating Summary:
    16 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten upgraded Intellia Therapeutics (NASDAQ: NTLA) from Neutral to Outperform with a price target of $21.00 (from $20.00).

  • ATTR IND in 2020; Cell Therapy Program at the Heels

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $14.82 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Upgrades